Mauro Sella
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mauro Sella has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Dacheng Shen
Department of Biomolecular Systems Max Planck Institute of Colloids and Interfaces Am Mühlenberg 1 14476 Potsdam Germany
2 shared publications - Julinton Sianturi
Department of Biomolecular Systems Max Planck Institute of Colloids and Interfaces Am Mühlenberg 1 14476 Potsdam Germany
2 shared publications - Patricia Priegue
Department of Biomolecular Systems Max Planck Institute of Colloids and Interfaces Am Mühlenberg 1 14476 Potsdam Germany
2 shared publications - Peter H. Seeberger
Department of Biomolecular Systems, Max-Planck-Institute of Colloids and Interfaces, Am Mühlenberg 1, 14476 Potsdam, Germany
2 shared publications - Shuo Zhang
Department of Chemistry, Massachusetts Institute of Technology, Cambridge, USA
2 shared publications
Latest Publications
- Open Access
- 14 April 2021
- Published by Wiley in Angewandte Chemie
- Vol. 133 (26) , 14800-14813
Discovery of Oligosaccharide Antigens for Semi‐Synthetic Glycoconjugate Vaccine Leads against Streptococcus suis Serotypes 2, 3, 9 and 14**
Streptococcus suis bacteria are one of the most serious health problems for pigs and an emerging zoonotic agent in humans working in the swine industry. S. suis bacteria express capsular polysaccharides (CPS) a major bacterial virulence factor that define the serotypes. Oligosaccharides resembling the CPS of S. suis serotypes 2, 3, 9, and 14 have been synthesized, glycans related to serotypes 2 and 9 were placed on glycan array surfaces to screen blood from infected pigs. Lead antigens for the development of semi‐synthetic S. suis serotypes 2 and 9 glycoconjugate veterinary vaccines were identified in this way.
- 14 April 2021
- Published by Wiley in Angewandte Chemie
- Vol. 133 (26) , 14800-14813
Open AccessDiscovery of Oligosaccharide Antigens for Semi‐Synthetic Glycoconjugate Vaccine Leads against Streptococcus suis Serotypes 2, 3, 9 and 14**
Streptococcus suis bacteria are one of the most serious health problems for pigs and an emerging zoonotic agent in humans working in the swine industry. S. suis bacteria express capsular polysaccharides (CPS) a major bacterial virulence factor that define the serotypes. Oligosaccharides resembling the CPS of S. suis serotypes 2, 3, 9, and 14 have been synthesized, glycans related to serotypes 2 and 9 were placed on glycan array surfaces to screen blood from infected pigs. Lead antigens for the development of semi‐synthetic S. suis serotypes 2 and 9 glycoconjugate veterinary vaccines were identified in this way.
- Open Access
- 14 April 2021
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 60 (26) , 14679-14692
Discovery of Oligosaccharide Antigens for Semi‐Synthetic Glycoconjugate Vaccine Leads against Streptococcus suis Serotypes 2, 3, 9 and 14**
Streptococcus suis bacteria are one of the most serious health problems for pigs and an emerging zoonotic agent in humans working in the swine industry. S. suis bacteria express capsular polysaccharides (CPS) a major bacterial virulence factor that define the serotypes. Oligosaccharides resembling the CPS of S. suis serotypes 2, 3, 9, and 14 have been synthesized, glycans related to serotypes 2 and 9 were placed on glycan array surfaces to screen blood from infected pigs. Lead antigens for the development of semi‐synthetic S. suis serotypes 2 and 9 glycoconjugate veterinary vaccines were identified in this way.
- 14 April 2021
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 60 (26) , 14679-14692
Open AccessDiscovery of Oligosaccharide Antigens for Semi‐Synthetic Glycoconjugate Vaccine Leads against Streptococcus suis Serotypes 2, 3, 9 and 14**
Streptococcus suis bacteria are one of the most serious health problems for pigs and an emerging zoonotic agent in humans working in the swine industry. S. suis bacteria express capsular polysaccharides (CPS) a major bacterial virulence factor that define the serotypes. Oligosaccharides resembling the CPS of S. suis serotypes 2, 3, 9, and 14 have been synthesized, glycans related to serotypes 2 and 9 were placed on glycan array surfaces to screen blood from infected pigs. Lead antigens for the development of semi‐synthetic S. suis serotypes 2 and 9 glycoconjugate veterinary vaccines were identified in this way.